R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiotechBoehringer Ingelheim

Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan

COVID-19SHE: 300142

Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial

AI

Tianhe-2 Supercomputer Aids Drug Discovery with Deep-Learning Biosynthetic Tool

Soaring Costs of Cynomolgus Monkeys Impact China’s Biologic Drug Development

Show More